EMA lists paediatric priorities for off-patent drugs as new EC funding nears
This article was originally published in Scrip
Following a two-year drought, the European Commission's seventh framework programme (FP7) is to make fresh funding available next year for companies wishing to develop paediatric forms of off-patent drugs.
You may also be interested in...
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.
The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.